rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2002-741rsp-878Research ArticleСтатьиArticlesКЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ИНТЕРЛЕЙКИНА-4 ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИCLINICAL IMPORTANCE OF INTERLEUKIN-4 IN SYSTEMIC SCLERODERMAНевскаяТ. А.NevskayaT A-RyazanlzevaT ARyazanlzevaT A-ГусеваН. Г.GusevaN G-200215022002401№1 (2002)913Copyright © Невская Т.А., Ryazanlzeva T.A., Гусева Н.Г., 20022002Невская Т.А., Ryazanlzeva T.A., Гусева Н.Г.Nevskaya T.A., Ryazanlzeva T.A., Guseva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/878

Цель. Изучить взаимосвязь сывороточного уровня интерлейкина-4 (ИЛ-4) с висцеральной патологией, характером течения и клиническими формами ССД. Материалы и методы. ИЛ-4 определялся в сыворотках 40 больных ССД непрямым твердофазным имму- нофермеитным методом (ELISA). Результаты. Уровень ИЛ-4 в пределах Ю-ЮООпг/мл выявлен у 12 из 40 больных ССД (30%). Отличительными особенностями этой группы больных были меньшая длительность заболевания, прогрессирование кожного фиброза и висцеральной патологии к моменту обследования и тенденция к большей частоте легочного фиброза. Существенных различий в поражении других внутренних органов, как и зависимости содержания ИЛ-4 от клинических форм и течения заболевания, выявлено не было. У больных с повышением ИЛ-4 в крови отмечены более высокие уровни ЦИК, у-глобулинов, в то время как содержание острофазовых реактантов было ниже, чем в остальной группе. Вывод. Установленная связь сывороточного уровня ИЛ-4 с активностью фиброзного процесса при ССД требует подтверждения в проспективных исследованиях.

The aim of the study was to investigate whether serum levels of interleukin-4 ( IL-4) reflects the clinical disease status and laboratory features of systemic sclerosis (SSc). IL-4 was measured by ELISA in forty patients wilh SSc. We revealed IL-4 (Ю-lOOOpg/ml) in sera from 12 of 40 pts (30%). These pts had significantly less duration of disease, the progression of skin and visceral involvement by the time of investigation and a trend lo the greater frequency of lung fibrosis. There was no correlation of IL-4 level with type of SSc. The pts with increased scrum levels of IL-4 had higher levels of circulated immune complexes, y-globulins, but the levels of acute phase reactants (CRP, fibrinogen) were lower compared with the of others. We suggest that serum IL-4 may serve a biologic marker for the progression of skin and lung fibrosis, but the results require confirmation in longitudinal study.

интерлейкин-4системная склеродермияТ лимфоцитыфиброзактивностьReferences<div><p>Atamas S.P., Yurovsky V.V., Wise R. Production of type 2 cytokines by CD8’ lung cclls is associated with greater decline in pulmonary function in patients with systemic sclcrosis. Arihr, Rheum., 1999, 42(6), 1168-78.</p><p>Ihn H„ Sato S., Fujimoto M. Demonstration of interleukin-2. interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch. Dermatol. Res., 1995, 287(2), 193-7,</p><p>Fertin C., Nicolas J.F., Gillcry P. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell. Mol. Biol., 1991, 37(8), 823-829.</p><p>Korn J.H. Systemic sclcrosis: current pathogenetic concepts and I'uture prospects for targeted therapy. Lancet., 1996, 347, 1455.</p><p>Kuroda K„ Shinkai H, Downregulatcd of decorin expression in dermal fibroblasts by interleukin-4. Arch. Dermatol. Res. 1997, 289, 476-480.</p><p>Lee K.S., Ro Y.J., Ryoo Y.W,, Kwon H.S. Regulation of intcr- leukin-4 on collagen gene expression in systemic sclerosis fibroblast culture.I. Dermatol. Sci„ 1996, 12(2), 110-117.</p><p>Needleman B.W., Fredrick M.W., Stair R.W. Interleukin-!, interleukin-2, interleukin-4, interleukin-6, tumor necrosis fac- lor a, and interferon-7 levels in sera from patients with scleroderma. Arthr. Rheum., 1992, 35(1), 67-72.</p><p>Ong C., Wong C., Roberts C.R., Teh H.S. Anti-IL-4 treatment prevents dermal collagen deposition in the light-skin mouse model of scleroderma. Eur. J. Immunol., 1998, 28(9). 26192629.</p><p>Picla-Stnilh Т.Н. Broketa G., Hand A., Korn J.H. Regulation of ICAM-I expression and function in human dermal fibroblasts by 1L-4. J. оГ Immunol., 1996, 145(5), 1375-1381.</p><p>Postlethwaits A.E. Role of T cells and cytokines in effecting fibrosis. Int. Rev. Immunol., 1995, 12(2-4), 247-258.</p><p>Salmon-Ehr V., Serpier H„ Nawrocki B. Expression of 1L-4 in scleroderma skin speciemeius and scleroderma fibroblast cultures. Potential role in fibrosis. Arch. Dermatol., 1996, 132(7), 802-806.</p><p>Sakkas L.I., Touriellolle Ch., Berney.1, Increased levels of alternatively spliced interleukin 4 (IL-4) transcripts in peripheral blood mononuclear cells from palients with systemic sclerosis. Clin, and Diagn. Lab. Immunology., 1999, 6(5), 660-664.</p><p>Serpier H., Gillery P., Salmon-Ehr V. Antagonistic effects of inlerferon-gamma and interleukin-4 on fibroblast cultures. J of Invest. Dermatology, 1997, 109, 158-162.</p><p>Szegedi A., Czirjak L., Unkeless J.C. Serum cytokine and nnti-FC gamma R autoantibody measurements in patients wilh systemic sclerosis. Acta. Derm. Venerol,, 1996, 76(1), 21-23.</p><p>Trojanowska M„ Le Roy E.C., Kekes B. and Kreig Th.Patho genesis of fibrosis: type I collagen and the skin. J. Mol. Med.,1998, 76, 266-274.</p><p>Y oshikaw a H., N akajim a Y., T asak a K. G lucocorticoid supress autocrine survival of mast cells by inhibiting IL-4 produc tion and ICAM-1 expression. J.Immunol., 1999, 162(10), 6162-6170.</p></div><br /><div><p>Atamas S.P., Yurovsky V.V., Wise R. Production of type 2 cytokines by CD8’ lung cclls is associated with greater decline in pulmonary function in patients with systemic sclcrosis. Arihr, Rheum., 1999, 42(6), 1168-78.</p><p>Ihn H„ Sato S., Fujimoto M. Demonstration of interleukin-2. interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch. Dermatol. Res., 1995, 287(2), 193-7,</p><p>Fertin C., Nicolas J.F., Gillcry P. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell. Mol. Biol., 1991, 37(8), 823-829.</p><p>Korn J.H. Systemic sclcrosis: current pathogenetic concepts and I'uture prospects for targeted therapy. Lancet., 1996, 347, 1455.</p><p>Kuroda K„ Shinkai H, Downregulatcd of decorin expression in dermal fibroblasts by interleukin-4. Arch. Dermatol. Res. 1997, 289, 476-480.</p><p>Lee K.S., Ro Y.J., Ryoo Y.W,, Kwon H.S. Regulation of intcr- leukin-4 on collagen gene expression in systemic sclerosis fibroblast culture.I. Dermatol. Sci„ 1996, 12(2), 110-117.</p><p>Needleman B.W., Fredrick M.W., Stair R.W. Interleukin-!, interleukin-2, interleukin-4, interleukin-6, tumor necrosis fac- lor a, and interferon-7 levels in sera from patients with scleroderma. Arthr. Rheum., 1992, 35(1), 67-72.</p><p>Ong C., Wong C., Roberts C.R., Teh H.S. Anti-IL-4 treatment prevents dermal collagen deposition in the light-skin mouse model of scleroderma. Eur. J. Immunol., 1998, 28(9). 26192629.</p><p>Picla-Stnilh Т.Н. Broketa G., Hand A., Korn J.H. Regulation of ICAM-I expression and function in human dermal fibroblasts by 1L-4. J. оГ Immunol., 1996, 145(5), 1375-1381.</p><p>Postlethwaits A.E. Role of T cells and cytokines in effecting fibrosis. Int. Rev. Immunol., 1995, 12(2-4), 247-258.</p><p>Salmon-Ehr V., Serpier H„ Nawrocki B. Expression of 1L-4 in scleroderma skin speciemeius and scleroderma fibroblast cultures. Potential role in fibrosis. Arch. Dermatol., 1996, 132(7), 802-806.</p><p>Sakkas L.I., Touriellolle Ch., Berney.1, Increased levels of alternatively spliced interleukin 4 (IL-4) transcripts in peripheral blood mononuclear cells from palients with systemic sclerosis. Clin, and Diagn. Lab. Immunology., 1999, 6(5), 660-664.</p><p>Serpier H., Gillery P., Salmon-Ehr V. Antagonistic effects of inlerferon-gamma and interleukin-4 on fibroblast cultures. J of Invest. Dermatology, 1997, 109, 158-162.</p><p>Szegedi A., Czirjak L., Unkeless J.C. Serum cytokine and nnti-FC gamma R autoantibody measurements in patients wilh systemic sclerosis. Acta. Derm. Venerol,, 1996, 76(1), 21-23.</p><p>Trojanowska M„ Le Roy E.C., Kekes B. and Kreig Th.Patho genesis of fibrosis: type I collagen and the skin. J. Mol. Med.,1998, 76, 266-274.</p><p>Y oshikaw a H., N akajim a Y., T asak a K. G lucocorticoid supress autocrine survival of mast cells by inhibiting IL-4 produc tion and ICAM-1 expression. J.Immunol., 1999, 162(10), 6162-6170.</p></div><br />

The authors declare that there are no conflicts of interest present.